RPG Life Sciences Raghava Life Sciences acquisition is a significant development in India’s pharmaceutical API sector. RPG Life Sciences, through its wholly owned subsidiary RPG Active Pharma Ltd. (RPGAP), has acquired the API and intermediates business of Hyderabad-based Raghava Life Sciences for up to ₹135 crore.
The acquisition will add a 300-KL manufacturing facility and a portfolio of 29 API molecules to RPG Active Pharma’s growing API platform.
Quick Summary
RPG Life Sciences is acquiring Raghava Life Sciences’ API and intermediates business for up to ₹135 crore through RPG Active Pharma. The deal adds a 300-KL EU-GMP-approved facility and 29 API molecules, including 22 commercialised APIs and 7 development-stage products.
RPG Life Sciences Raghava Life Sciences Acquisition: Overview
The acquisition is part of RPG Active Pharma’s strategy to build a larger and integrated Active Pharmaceutical Ingredients (API) business.
The Hyderabad-based Raghava facility provides additional manufacturing capacity, products and regulatory capabilities. RPG Active Pharma expects the acquired plant to have the potential to generate around ₹200 crore in revenue at full utilisation.
Key Highlights
| Particular | Details |
|---|---|
| Acquirer | RPG Active Pharma Ltd. |
| Parent Company | RPG Life Sciences |
| Target | Raghava Life Sciences |
| Deal Value | Up to ₹135 crore |
| Business Acquired | APIs and intermediates |
| Manufacturing Capacity | 300 KL |
| API Portfolio | 29 molecules |
| Commercialised APIs | 22 |
| Development-Stage APIs | 7 |
| Facility Approval | EU-GMP approved |
| Location | Hyderabad |
| Revenue Potential | Around ₹200 crore at full utilisation |
What Is Being Acquired?
RPG Active Pharma is acquiring the API and intermediates business of Raghava Life Sciences.
The transaction provides access to a 300-KL manufacturing facility located near Hyderabad. The facility has an API portfolio covering multiple therapeutic areas, including:
- Diabetes
- Cardiovascular diseases
- CNS-related therapies
The portfolio includes 29 molecules, of which 22 are commercialised and 7 are at the development stage.
RPG Active Pharma’s Second Acquisition
The Raghava Life Sciences deal is the second acquisition by RPG Active Pharma since RPG Life Sciences separated its API business into a standalone subsidiary.
Before this transaction, RPG Active Pharma acquired Actis Generics for around ₹80 crore.
These acquisitions form part of a broader buy-and-build strategy aimed at creating a scaled and integrated API platform.
Earlier Acquisition
| Acquisition | Approximate Value | Strategic Focus |
|---|---|---|
| Actis Generics | ₹80 crore | API and intermediate manufacturing |
| Raghava Life Sciences API Business | Up to ₹135 crore | APIs, intermediates and manufacturing capacity |
What Does the Raghava Acquisition Add to RPG Active Pharma?
The acquisition can strengthen RPG Active Pharma in several important areas.
1. Additional Manufacturing Capacity
The company gains access to a 300-KL manufacturing facility, increasing its overall production capabilities.
2. Larger API Portfolio
The acquired business adds 29 API molecules, providing RPG Active Pharma with a broader product portfolio.
3. Regulatory Capabilities
The facility is EU-GMP approved, which can support the company’s participation in regulated pharmaceutical markets.
4. Growth Potential
The facility generated approximately ₹19 crore in revenue in FY2026, while its estimated revenue potential at full utilisation is around ₹200 crore.
This difference indicates significant scope for improving capacity utilisation and expanding the business.
Investment from InvAscent
The acquisition is supported by the investment made by healthcare-focused private equity firm InvAscent in RPG Active Pharma.
InvAscent had committed up to ₹700 crore to RPG Active Pharma. The initial equity investment was approximately ₹243 crore for a 40% stake.
The funding is intended to support RPG Active Pharma’s expansion through acquisitions and other growth initiatives.
Revenue Potential of the Acquired Business
The Raghava API business reported approximately ₹19 crore in revenue in FY2026.
However, RPG Life Sciences estimates that the facility has the potential to generate around ₹200 crore in revenue at full utilisation.
| Metric | Value |
|---|---|
| FY2026 Revenue | Approx. ₹19 crore |
| Potential Revenue at Full Utilisation | Approx. ₹200 crore |
| Manufacturing Capacity | 300 KL |
The expected increase in utilisation could therefore become an important growth opportunity for RPG Active Pharma.
Why Is This Acquisition Important?
The transaction is strategically important because it can help RPG Active Pharma build scale in the API market.
The acquisition may help the company:
- Expand its API manufacturing footprint
- Increase its product portfolio
- Add manufacturing capacity
- Strengthen regulatory capabilities
- Improve capacity utilisation
- Create synergies with its existing businesses
- Expand customer reach
- Build a larger integrated API platform
Why Is API Manufacturing Important in the Pharmaceutical Industry?
Active Pharmaceutical Ingredients (APIs) are the substances responsible for producing the intended therapeutic effect of a medicine.
A strong API manufacturing base is important for pharmaceutical companies because it can support:
- Reliable supply of essential drug ingredients
- Product development
- Manufacturing scale-up
- Regulatory compliance
- Domestic pharmaceutical production
- Export opportunities
India is an important global pharmaceutical manufacturing hub, making API capacity and capabilities strategically significant for Indian pharma companies.
Why Should Pharmacy Candidates Know About This Acquisition?
Although this acquisition is primarily a pharmaceutical business development, it is relevant to B.Pharm, M.Pharm and other pharmacy students interested in the pharmaceutical industry.
Understanding major pharma acquisitions can help students learn about:
- API manufacturing
- Pharmaceutical business strategy
- Drug development
- Regulatory compliance
- GMP and EU-GMP facilities
- Pharmaceutical manufacturing careers
- Growth of India’s pharma industry
For pharmacy job aspirants, developments like these can also provide useful industry awareness for interviews, group discussions and competitive exam preparation.
Frequently Asked Questions (FAQs)
1. What did RPG Life Sciences acquire from Raghava Life Sciences?
RPG Life Sciences, through RPG Active Pharma Ltd., acquired the API and intermediates business of Raghava Life Sciences.
2. What is the value of the Raghava Life Sciences acquisition?
The acquisition is valued at up to ₹135 crore.
3. What manufacturing capacity does the acquired facility have?
The acquired facility has a manufacturing capacity of approximately 300 KL.
4. How many API molecules are included in the acquisition?
The acquired business has a portfolio of 29 API molecules.
5. How many APIs are already commercialised?
Of the 29 molecules, 22 are commercialised, while 7 are under development.
6. Where is the acquired Raghava facility located?
The manufacturing facility is located near Hyderabad.
7. What is the revenue potential of the facility?
RPG Life Sciences estimates that the facility could generate approximately ₹200 crore in revenue at full utilisation.
8. Is this RPG Active Pharma’s first acquisition?
No. The Raghava transaction is described as RPG Active Pharma’s second acquisition after the API business was separated into a standalone subsidiary. Its earlier acquisition was Actis Generics for around ₹80 crore.
Important Details at a Glance
| Category | Information |
|---|---|
| Company | RPG Life Sciences |
| Subsidiary | RPG Active Pharma Ltd. |
| Target Business | Raghava Life Sciences API & Intermediates |
| Acquisition Value | Up to ₹135 crore |
| Facility Capacity | 300 KL |
| API Molecules | 29 |
| Commercialised APIs | 22 |
| Development APIs | 7 |
| Regulatory Status | EU-GMP approved |
| Facility Location | Hyderabad |
| FY2026 Revenue | Approx. ₹19 crore |
| Full-Utilisation Revenue Potential | Approx. ₹200 crore |
Conclusion
The RPG Life Sciences Raghava Life Sciences acquisition for up to ₹135 crore is an important step in RPG Active Pharma’s plan to expand its API business.
The deal adds a 300-KL manufacturing facility, 29 API molecules and an EU-GMP-approved facility to the company’s platform. With 22 commercialised APIs and seven development-stage molecules, the acquisition also provides opportunities for portfolio expansion and increased capacity utilisation.
With support from InvAscent and its ongoing buy-and-build strategy, RPG Active Pharma is working toward creating a larger and more integrated API business in India and global markets.
Recommended Products
